Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27190105 | 0.83 | — | — | |
| SCHEMBL29985419 | 0.75 | POLB (0.35) | POLBCYP1A2 | |
| SCHEMBL30493922 | 0.73 | POLB (0.44) | POLBCYP1A2KMT2AHTR7 | |
| SCHEMBL29985164 | 0.72 | POLB (0.47) | POLBCYP1A2KMT2A | |
| SCHEMBL29542823 | 0.70 | POLB (0.44) | POLBCYP1A2KMT2A | |
| SCHEMBL30493896 | 0.70 | POLB (0.44) | POLBCYP1A2KMT2AHTR7 | |
| SCHEMBL22820392 | 0.68 | — | — | |
| SCHEMBL20669147 | 0.68 | POLB (0.56) | POLBCYP1A2KMT2A | |
| SCHEMBL12735554 | 0.68 | POLB (0.50) | POLBCYP1A2KMT2A | |
| SCHEMBL30493914 | 0.68 | POLB (0.42) | POLBCYP1A2KMT2AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624053-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260070930-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT | 2026-03-12 | — | — | US | disclosed |
| US-20250388608-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-12-25 | — | — | US | disclosed |
| US-20250197423-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-06-19 | — | — | US | disclosed |
| US-20250145643-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-05-08 | — | — | US | disclosed |
| CN-119798279-A | RAS inhibitors | 锐新医药公司 | 2025-04-11 | — | — | CN | disclosed |
| EP-4463231-A1 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| CN-118922423-A | RAS inhibitors | 锐新医药公司 | 2024-11-08 | — | — | CN | disclosed |
| CN-118561952-A | RAS inhibitors | 锐新医药公司 | 2024-08-30 | — | — | CN | disclosed |
| US-20240277796-A1 | METHODS FOR INHIBITING RAS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2024-08-22 | — | — | US | disclosed |
| EP-4346898-A1 | METHODS FOR INHIBITING RAS | Revolution Medicines, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-4334321-A1 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| WO-2023133543-A1 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2023-07-13 | — | — | WO | disclosed |
| US-20230106174-A1 | RAS INHIBITORS | Revolution Medicines, Inc. | 2023-04-06 | — | — | US | disclosed |
| WO-2022251292-A1 | METHODS FOR INHIBITING RAS | Revolution Medicines, Inc. (US) | 2022-12-01 | — | — | WO | disclosed |
| WO-2022235864-A1 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2022-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070930-A1 | RAS INHIBITORS | KRAS, NRAS, RIN1 | POLB 4419/4885CYP1A2 2007/4885KMT2A 4067/4885 |
| US-20250145643-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | POLB 3235/4885CYP1A2 4576/4885KMT2A 3685/4885 |
| US-12624053-B2 | Ras inhibitors | KRAS, NRAS, HMGCR | POLB 4448/4885CYP1A2 1927/4885KMT2A 3666/4885 |
| US-20250197423-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | POLB 3235/4885CYP1A2 4576/4885KMT2A 3685/4885 |
| US-20240277796-A1 | METHODS FOR INHIBITING RAS | KRAS, HRAS, NRAS | POLB 2161/4885CYP1A2 4859/4885KMT2A 3181/4885 |
| US-20250388608-A1 | RAS INHIBITORS | KRAS, NRAS, HMGCR | POLB 4448/4885CYP1A2 1927/4885KMT2A 3666/4885 |
| US-20230106174-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | POLB 3235/4885CYP1A2 4576/4885KMT2A 3685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.